Sigma-Aldrich Reaches New 1-Year High at $105.00 (SIAL)
Sigma-Aldrich (NASDAQ:SIAL) shares hit a new 52-week high during mid-day trading on Wednesday , American Banking News reports. The company traded as high as $105.00 and last traded at $103.98, with a volume of 108,102 shares changing hands. The stock had previously closed at $103.99.
SIAL has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Sigma-Aldrich in a research note on Tuesday, August 12th. They now have a $107.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sigma-Aldrich in a research note on Friday, July 25th. They now have a $97.00 price target on the stock, up previously from $95.00. Finally, analysts at Citigroup Inc. initiated coverage on shares of Sigma-Aldrich in a research note on Thursday, July 17th. They set a “neutral” rating and a $107.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $92.33.
The stock has a 50-day moving average of $102.6 and a 200-day moving average of $98.1. The company has a market cap of $12.317 billion and a price-to-earnings ratio of 24.58.
Sigma-Aldrich (NASDAQ:SIAL) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.11 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.11. The company had revenue of $701.00 million for the quarter, compared to the consensus estimate of $706.14 million. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Analysts expect that Sigma-Aldrich will post $4.36 EPS for the current fiscal year.
Sigma-Aldrich Corporation is a life science and high technology company. The Company develops, manufactures, purchases and distributes the range of chemicals, biochemicals and equipment available globally and also provides global biopharmaceutical testing services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.